

# CITATION REPORT

List of articles citing

## Experimental Pharmacotherapy for COVID-19: The Latest Advances

DOI: 10.2147/jep.s255209

Journal of Experimental Pharmacology, 2021, 13, 1-13.

**Source:** <https://exaly.com/paper-pdf/82700010/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Repurposing FDA-approved drugs to fight COVID-19 using methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations. <i>Informatix in Medicine Unlocked</i> , <b>2021</b> , 23, 100541	5.3	9
18	Characteristics of viral pneumonia in the COVID-19 era: an update. <i>Infection</i> , <b>2021</b> , 49, 607-616	5.8	14
17	Gender differences in vaccine therapy: where are we in COVID-19 pandemic?. <i>Monaldi Archives for Chest Disease</i> , <b>2021</b> ,	2.7	5
16	PD-L1 Dysregulation in COVID-19 Patients. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 695242	8.4	16
15	Environmental impact assessment of COVID-19 therapeutic solutions. A prospective analysis. <i>Science of the Total Environment</i> , <b>2021</b> , 778, 146257	10.2	13
14	Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	7
13	An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 1-10	6.2	7
12	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 752227	8.4	5
11	Krebs von den Lungen 6 levels in COVID-19 ICU Patients are Associated with Mortality.		
10	Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?. <i>Pharmacopsychiatry</i> , <b>2022</b> , 55, 7-15	2	3
9	Socio-demographic characteristics and their relation to medical service consumption among elderly in Israel during the COVID-19 lockdown in 2020 compared to the corresponding period in 2019.		0
8	Rifampicin for COVID-19.. <i>World Journal of Virology</i> , <b>2022</b> , 11, 90-97	6.9	0
7	Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	2
6	Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e227970	10.4	4
5	Hematological- and Immunological-Related Biomarkers to Characterize Patients with COVID-19 from Other Viral Respiratory Diseases. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3578	5.1	0
4	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. 1-14		2
3	Socio-demographic characteristics and their relation to medical service consumption among elderly in Israel during the COVID-19 lockdown in 2020 as compared to the corresponding period in 2019. <b>2022</b> , 17, e0278893		0

2 The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). 1-13 1

1 Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches. 2023, 13, 334 1